NTRA News and Press, Natera Inc. From 12/09/22

Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers PR Newswire Across all subtypes, in a real-world cohort of >200 patients and >900 plasma samples, the presence of ctDNA at any time w...

Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium PR Newswire AUSTIN, Texas , Dec. 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans t...

Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT PR Newswire Study aligns with Natera's longstanding commitment to generate robust, real-world clinical evidence and highlights uniqu...

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference PR Newswire AUSTIN, Texas , Nov. 23, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman , ...

New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients PR Newswire ctDNA reduction at week nine in patients treated with tebentafusp was associated with improved o...

Natera ( NASDAQ: NTRA ) has priced its underwritten public offering of 11.43M shares of its common stock at a price to the public of $35.00/share. Closing of the offering is expected to occur on November 18, 2022. Underwriters are granted a 30-day option to purcha...

Summary CareDx reported lackluster performance in the third quarter, with core testing revenue down by 2.5%, mirroring intensifying competitive dynamics impacting its pricing power. Competitive dynamics are exacerbated by the company's expansion in niche markets with structurally ...

Natera, Inc. ( NASDAQ: NTRA ) shares dropped ~10% Wednesday to reach the lowest level since July despite reporting better-than-expected financials for Q3 as the molecular test maker lowered full-year guidance for gross margin. However, the company raised its 2022 rev...

Natera, Inc. (NTRA) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager, Oncology Conference Call Participant...

Natera press release ( NASDAQ: NTRA ): Q3 GAAP EPS of -$1.25 beats by $0.20 . Revenue of $210.64M (+33.2% Y/Y) beats by $3.98M. Product revenues grew 29.8% over the same period. Outlook: 2022 revenue guidance raised to $810 million – $830 million, up...